HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Visser, M.J. Articles by Duiverman, E.J. Search for Related Content PubMed PubMed Citation Articles by Visser, M.J. Articles by Duiverman, E.J.

Side-effects of fluticasone in asthmatic children: no effects after dose reduction

Depts of ¹ Pulmonology, ² Pathology and Laboratory Medicine, ⁶ Paediatric Pulmonology, University Hospital Groningen, ³ Dept of Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam, ⁴ Dept of Paediatrics, Medical Centre, Leeuwarden, and ⁵ Dept of Paediatrics, Division of Paediatric Pulmonology, Isala Klinieken, Zwolle, the Netherlands

CORRESPONDENCE: M.J. Visser, Dept of Pulmonology, University Hospital Groningen, P.O.Box 30,001, 9700 RB, Groningen, the Netherlands. Fax: 31 503619320. E-mail: M.Visser@int.azg.nl

Keywords: Adrenal cortex, bone metabolism, fluticasone, height, hyperresponsiveness

Received: February 25, 2004
Accepted April 20, 2004

This study was supported by GlaxoSmithKline (the Netherlands), De Stichting Astma Bestrijding, University Hospital Groningen and the University of Groningen.

To assess long-term effects and side-effects of fluticasone propionate (FP), a 2-yr study was performed, comparing a step-down dose approach (1,000 µg·day^–1, with reductions every 2 months to 500, 200 and 100 µg·day^–1 for the remainder of the study) versus a constant dose (200 µg·day^–1).

In 55 children with chronic persistent asthma, aged 6–10 yrs, airways hyperresponsiveness (AHR) and systemic side-effects (height, bone parameters and adrenal cortical function) were assessed at predetermined intervals in a double-blind prospective 2-yr study.

AHR improved after 4 months treatment with 1,000 µg·day^–1 FP followed by 500 µg·day^–1, without significant differences during long-term treatment between the two approaches. Dose-dependent reduction of growth velocity, adrenal cortical function and biochemical bone turnover was found during therapy with 1,000 and 500 µg·day^–1 FP when compared with 200 µg·day^–1.

In conclusion, doses of 1,000 and 500 µg·day^–1 fluticasone propionate are associated with marked reductions of growth velocity, bone turnover and adrenal cortical function. However, conventional doses (200 µg·day^–1 fluticasone propionate) appear to be safe in the long-term management of childhood asthma. From a safety point of view, high doses of fluticasone propionate should only be prescribed in exceptions, e.g. in persistent severe asthma.

This article has been cited by other articles:

				G Russell Very high dose inhaled corticosteroids: panacea or poison? Arch. Dis. Child., October 1, 2006; 91(10): 802 - 804. [Full Text] [PDF]

				A. D. Smith, J. O. Cowan, K. P. Brassett, G. P. Herbison, and D. R. Taylor Use of Exhaled Nitric Oxide Measurements to Guide Treatment in Chronic Asthma N. Engl. J. Med., May 26, 2005; 352(21): 2163 - 2173. [Abstract] [Full Text] [PDF]